Clinical Trial Update: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort [Phase 2]

View source ↗

Summary

Results have been posted for a Phase 2 trial comparing crenezumab to placebo in individuals with autosomal-dominant Alzheimer's disease due to PSEN1 E280A, incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Autosomal-dominant Alzheimer Disease

Drugs mentioned

• Crenezumab

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-09-22